Insight · EU MDR · Cardiology CER
For a cardiac device, the clinical evaluation report is where CE marking is won or lost. A strong device with a weak CER still fails review, and in cardiology, where most devices are high-risk, the CER is held to the most demanding standard in the regulation.
European Champion
Platinum Award 2026
Eclevar MedTech & Milo Health · xShare × EUCROF Open Call
Led by authority
The pattern we see is consistent: teams treat the clinical evaluation report file as documentation to assemble, when the Notified Body treats it as an argument to test. The people accountable for your file have sat on both sides of the submission.
Cardiac surgeon and former lead Notified Body reviewer at TÜV SÜD. 400+ devices CE-certified.
in LinkedIn
Former clinical reviewer at TÜV SÜD for Class III implants; PMCF and CER methodology.
in LinkedIn
CERs under MEDDEV 2.7/1 Rev 4 and EU MDR, and Notified Body deficiency response.
in LinkedInWhy the bar is higher
Most cardiovascular devices are Class IIb or Class III, and for Class III the clinical evidence requirements sit at the top of the MDR pyramid.
The evidence, not the device
A cer cardiology eu mdr file generally cannot lean on literature and equivalence alone: a pre-market clinical investigation is expected under Article 61 unless equivalence is fully and narrowly demonstrated. The reviewer is testing whether the evidence actually supports the specific claims, for this device, at this classification. Shaping that argument early is the core of a sound cardiovascular clinical strategy.
Scrutiny scaled to consequence
A cardiovascular device acts on the circulatory system, where a failure can be immediately life-threatening, and a Notified Body calibrates its scrutiny to that consequence. The same clinical evaluation that would pass for a low-risk device is read far more critically when the device is a cardiac implant, because the cost of an unsupported claim is measured in patient harm.
That scrutiny falls hardest on the clinical data itself. For a Class III cardiac device, a reviewer expects evidence that the device performs in the specific indication claimed, in a population representative of real use, followed long enough to see the outcomes that matter. A CER that leans on short follow-up, a narrow cohort, or data from a different device configuration leaves exactly the gaps a cardiology reviewer is trained to find. Robust follow-up depends on disciplined clinical monitoring across every site.
A moving standard
Cardiovascular practice and the competing technologies evolve quickly, so a state of the art that was defensible two years ago may already be outdated, and a CER built on it can show the device clearing a standard the field has moved beyond. Keeping the state of the art current, and the benefit-risk anchored to it, is part of what keeps a cardiology CER alive through renewal, and it is exactly what a live post-market clinical follow-up programme is built to do.
None of this means the bar is unreachable. Cardiology CERs pass every day, but they pass because the evidence was planned to the standard from the outset rather than reverse-engineered to fit a deadline. The manufacturers who clear review cleanly are the ones who treated the clinical evaluation as the core of the regulatory strategy, not the paperwork bolted on at the end of it.
A useful way to picture the standard is to ask what a cardiology assessor is protecting. Their job is to be sure that a device acting on the heart or vasculature does what its label claims, in the patients who will actually receive it, with risks that are understood and acceptable. Every element of the CER is read against that question, and a report that cannot answer it plainly, with evidence rather than assertion, will not satisfy a reviewer however well it is written.
Talk to a reviewer
Book a free scoping call with a CER lead and a former Notified Body reviewer. Bring your device and your claims, and get a checkable read on where the argument holds.
Book a free scoping callThe structural failures
These four failures share a root cause: a CER assembled as a document at the end, rather than planned as an argument from the start.
When the clinical evaluation plan is written after the data exists, the equivalence claim is stretched to cover a gap, or the state of the art is sketched rather than established, the weaknesses are baked in before the report is even drafted, and no amount of editing fixes a foundation that was never laid.
Each failure is also predictable, which means it is preventable. A reviewer who has assessed cardiac files knows to check whether the plan pre-dates the report, whether the equivalence conditions are actually met, whether the state of the art is defensible, and whether every residual gap routes to a named post-market activity. Running that same check on your own file, as part of an MDR technical review before submission, surfaces the blockers while they can still be fixed.
The cost of missing them is measured in time. A cardiology CER sent back for any of these reasons costs a review cycle, and for a device working against a certificate deadline a lost cycle can be the difference between keeping the market and losing it. The cheapest moment to find these gaps is during the evaluation, not in a deficiency letter.
It is worth separating the four blockers from the dozens of minor comments a CER attracts. Minor comments are normal and easily resolved; the four blockers are structural, because each one undermines the report's core argument rather than a detail of it. A manufacturer triaging a deficiency letter should fix the structural issues first, since clearing a list of small points while leaving a broken equivalence claim or an absent state of the art simply invites the same rejection a cycle later.
The four blockers
See the method
Explore our clinical evaluation report service: how the CEP-to-CER argument is structured for the reviewer, from state of the art to PMCF.
Explore the CER serviceWhat good looks like
It reads as a continuous argument: a CEP that frames the claims, a literature and SOTA review that benchmarks them, clinical data (investigation and/or sound equivalence) that supports them, a quantified benefit-risk, and a PMCF plan that closes what remains. Structured per MDCG 2020-13 and Annex XIV Part A, it answers the reviewer's questions before they are asked.
A passing CER reads as one continuous argument rather than a binder of assembled parts. The plan frames the claims, the literature and the clinical data answer them, the state of the art sets the benchmark, the benefit-risk weighs the evidence against that benchmark, and the post-market plan closes whatever remains open. A reviewer can follow the thread from claim to conclusion without hitting a break, and that coherence is itself a signal of control.
It also anticipates the questions before they are asked. Where the data has a limitation, the CER names it and explains how the post-market follow-up addresses it, rather than leaving the reviewer to discover it. A limitation the manufacturer raises and answers is far less damaging than one the reviewer finds, and a cardiology CER that does this consistently reads as the work of people who know what an assessor looks for.
Finally, it is built to survive renewal, not just initial certification. Because cardiovascular evidence standards keep rising, a CER that is only just adequate today is exposed at the next review, so the strongest files build in margin: stronger data, a current state of the art, and a live post-market programme that keeps the evidence fresh, often drawing on real-world evidence from cardiovascular registries. That forward design is what turns a CER from a one-time hurdle into a durable asset.
The practical test, before any submission, is whether someone outside the project can read the CER and follow the argument from intended purpose to conclusion without needing the authors to explain it. If the thread only holds together with verbal commentary, the reviewer, who gets no such commentary, will see the gaps. A CER that stands on its own page, defensible without its authors in the room, is the one that passes cardiology review cleanly.
Eclevar builds and remediates cardiology CERs with former Notified Body reviewers, the people who used to assess these dossiers now build them. As a specialist medical device CRO, we structure the CEP-to-CER argument, stress-test equivalence, and map every gap to PMCF before the file reaches the Notified Body.
Proof in practice
Real programmes built on endpoints and statistics that hold up with Notified Bodies and reimbursement reviewers. See client success stories →
A multicentre transcatheter aortic valve implantation study across eight UK sites, feeding the clinical evidence a cardiology CER and reimbursement dossier rely on.
A randomised study on chronic wound devices, captured on a validated EDC under ISO 14155, the kind of prospective evidence a high-risk CER is built on.
Proof, not adjectives
Awards, funding, accountability
Won by the Milo Health platform in the xShare Open Call for Clinical Research, the top Platinum tier: independent recognition, externally judged, scoped to what was awarded.
Top tier at the xShare × EUCROF Open Call, awarded to Eclevar MedTech and its Milo Health platform, presented at EUCROF 2026 in Amsterdam.
The announcement →Selected through the xShare Open Call for clinical research innovation, Horizon Europe.
xShare results →Distinction confirmed by an independent third party, the CVBF, also an awardee of the xShare × EUCROF Open Call.
CVBF coverage →
Official Eclevar resources
PMCF Studies · Regenerative Medicine · 5 EU Countries
Eclevar manages RegenLab's PMCF programme on chronic wound devices: a randomised study of 160 patients across 14 sites in 5 EU countries, covering diabetic foot ulcer (DFU) and venous leg ulcer (VLU) indications. The partnership combines Eclevar's ISO 14155 clinical expertise with the Milo Studio platform.
"Eclevar, with its tailor-made approach and advanced Milo Studio platform, represents a major strategic asset."Antoine Turzi, CEO, RegenLab
A whitepaper co-signed by BSI and Eclevar on the clinical requirements of EU MDR.
Read the whitepaper →Clinicians and a former Notified Body reviewer, named, not handed to a junior account team. Meet the full leadership team →
If your cardiology CER is heading into Notified Body review, or has come back with questions, the fastest path is an expert read before you resubmit. We will tell you where the argument holds and where it does not.
Book a free scoping callQuestions we hear first
